Loading clinical trials...
Loading clinical trials...
Phase I/II Multicenter Study to Assess Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
Conditions
Interventions
Topotecan
Temozolomide
+1 more
Locations
6
United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Cohen Children's Medical Center of New York
New Hyde Park, New York, United States
St Jude s Childrens Research Hospital
Memphis, Tennessee, United States
Novartis Investigative Site
Cologne, Germany
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Sutton, Surrey, United Kingdom
Start Date
December 27, 2022
Primary Completion Date
February 26, 2025
Completion Date
February 26, 2025
Last Updated
October 10, 2025
NCT04936529
NCT06541262
NCT04851119
NCT03363373
NCT03050268
NCT05890781
Lead Sponsor
Novartis Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions